

Eptifibatide

0.75 mg/mL Solution for infusion
& 2 mg/mL Solution for injection



In Canada, eptifibatide is indicated for:

- the treatment of patients presenting with symptoms of unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI), including those patients who may subsequently undergo percutaneous coronary intervention (PCI) as well as those who will be managed medically.
- the treatment of patients undergoing PCI including those undergoing intracoronary stenting.

ORDERING INFORMATION

JUNO #	WHOLESALER	CODE	STRENGTH	UPC / GTIN
900-002	McKessen	179830	0.75 mg/mL	5060467000208
	CPDN	800208		
900-003	McKessen	179829	2 mg/mL	5060467000192
	CPDN	800192		

juno.
PHARMACEUTICALS CANADA

For product and partnership enquiries please contact: sales@junopharm.com

For customer ordering please contact: customerservice@junopharm.com



Visit us at junopharm.ca

Juno Pharmaceuticals Canada | Advancing the Healthcare of Canadians

402-2233 Argentia Road, Mississauga ON L5N 2X7 P +1 888 882 8827 F +1 905 829 3810 www.junopharm.ca [in linkedin.com/company/juno-pharmaceuticals-canada](https://www.linkedin.com/company/juno-pharmaceuticals-canada)